^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GPRC5D inhibitor

    Related drugs:
    1d
    TALMMY1001-PT3: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=510, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2026 --> Jun 2027
    Trial primary completion date • First-in-human
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs)
    1d
    MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=166, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2027 --> Oct 2027
    Trial completion date
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs)
    8d
    QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P2 trial
    |
    lenalidomide • dexamethasone • pomalidomide • dexamethasone injection
    10d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | N=468 --> 795
    Enrollment change
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    14d
    R17372-HM-2493: A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myeloma (2025-522776-93-00)
    P1, N=26, Not yet recruiting, Regeneron Pharmaceuticals Inc.
    New P1 trial • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    17d
    A Preliminary Case Study to Evaluate the Efficacy and Safety of Talquetamab in Patients with Refractory Generalized Myasthenia Gravis (ChiCTR2600121843)
    P=N/A, N=2, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
    New trial
    |
    Talvey (talquetamab-tgvs)
    24d
    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    24d
    EMN37 fitfix: Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. (clinicaltrials.gov)
    P2, N=150, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    26d
    BP42233: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) (clinicaltrials.gov)
    P1, N=225, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    forimtamig (RG6234)
    26d
    MonumenTAL-3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (clinicaltrials.gov)
    P3, N=864, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2029 --> May 2028 | Trial primary completion date: Feb 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • dexamethasone injection
    26d
    MajesTEC-7: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=1590, Recruiting, Janssen Research & Development, LLC | N=568 --> 1590
    Enrollment change
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    26d
    MAGENTA: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=25, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • Talvey (talquetamab-tgvs) • mezigdomide (CC-92480)